Monopar Therapeutics

MNPR

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001645469

None

No letter

5 of 13 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $140.7M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	thin data, degenerate inputs not computable: distress, fortress balance sheet
Inputs computable	5 of 13
Graded from	filings received through Apr 1, 2026 233 days before the rescan; latest periodic filing 10-Q received Nov 12, 2026
Last close	$70.24 2026-11-19; market equity $476.0M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 27, 2026

- License, Development and Collaboration Agreements." Pursuant to the terms of our license agreement with AstraZeneca for ALXN1840, we obtained the intellectual property portfolio for ALXN1840, including exclusive license and prosecution of over 86 patent applications granted, published, or pending in over 30 countries worldwide. ALXN1840 has been granted Orphan Drug Designation for the treatment of Wilson disease in the U.S. and the EU, as well as Fast Track designation from the FDA. In the U.S., these include 6 granted patents, 7 published patent applications, and 1 private and pending application with the earliest expiration expected in 2038.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 78.3						
Gross profitability	not computable	32.8%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on invested capital	not computable	9.6%				
one or more required annual facts are missing						
Accruals ratio	(1.5%)	(6.7%)		78.3	756	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 0.1						
Altman Z double-prime	53.62	0.31		0.1	705	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(3.61x)				
one or more required annual facts are missing						
Current ratio	51.35x	2.68x		0.1	781	2025-12-31
Growth and financing, sleeve percentile 26.1						
Revenue growth, three-year compound	not computable	9.6%				
four consecutive annual observations are required						
Free cash flow growth, three-year compound	not computable	11.1%				
four consecutive annual FCF observations are required; found 0						
Reinvestment rate	not computable	33.9%				
one or more required annual facts are missing						
Asset growth, three years	119.9%	3.2%		1.7	663	2025-12-31
Net share issuance, one year	9.5%	1.6%		50.5	625	2026-03-17

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	5 of 13 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor

What the price implies

at the 2026-11-19 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(7.5%)	(1.7%)	44
Distance from 52-week high	(43.2%)	(31.7%)	39
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	not computable	0.6%	
Book value to price	0.27	0.29	47
Sales to price	0.00	0.37	0
Composite equity issuance, five years	99.2%	13.5%	83
Relative strength against the sector, log excess return	(0.25)	(0.19)	44
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$52.6M
Operating cash flow, four quarters	-$16.0M
Months of runway	39.6
Days since last periodic filing	8 (10-Q received Nov 12, 2026)
Median daily dollar volume, 63 sessions	$11.2M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$13.7M	2025-12-31	2026-03-27	10-K	26-010025
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$12.2M	2025-12-31	2026-03-27	10-K	26-010025
3	assets	us-gaap:Assets	$140.7M	2025-12-31	2026-03-27	10-K	26-010025
4	assets	us-gaap:Assets	$60.3M	2024-12-31	2026-03-27	10-K	26-010025
5	current assets	us-gaap:AssetsCurrent	$140.5M	2025-12-31	2026-03-27	10-K	26-010025
6	current liabilities	us-gaap:LiabilitiesCurrent	$2.7M	2025-12-31	2026-03-27	10-K	26-010025
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$89.5M	2025-12-31	2026-03-27	10-K	26-010025
8	operating income	us-gaap:OperatingIncomeLoss	-$16.7M	2025-12-31	2026-03-27	10-K	26-010025
9	book equity	us-gaap:StockholdersEquity	$137.8M	2025-12-31	2026-03-27	10-K	26-010025
10	liabilities	us-gaap:Liabilities	$2.9M	2025-12-31	2026-03-27	10-K	26-010025
11	revenue	us-gaap:Revenues	$0	2025-12-31	2026-03-27	10-K	26-010025
12	revenue	us-gaap:Revenues	$0	2024-12-31	2025-03-31	10-K	25-009979
13	revenue	us-gaap:Revenues	$0	2019-12-31	2020-03-27	10-K	20-003363
14	revenue	us-gaap:Revenues	$0	2018-12-31	2020-03-27	10-K	20-003363
15	assets	us-gaap:Assets	$7.3M	2023-12-31	2025-03-31	10-K	25-009979
16	assets	us-gaap:Assets	$13.2M	2022-12-31	2024-03-28	10-K	24-009687
17	shares outstanding	dei:EntityCommonStockSharesOutstanding	6,692,140	2026-03-17	2026-04-01	10-K/A	26-010841
18	shares outstanding	dei:EntityCommonStockSharesOutstanding	6,112,593	2025-03-14	2025-03-31	10-K	25-009979

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.